ClinicalTrials.gg
Status unknownNCT01574001Updated May 15, 2013

Smoking Cessation Interventions in Stroke Patients

An interventional study of Antismoking intervention with no early follow-up and Antismoking intervention with minimal early follow-up in Ischemic Stroke, sponsored by Institute of Psychiatry and Neurology, Warsaw. Status unknown at 1 site in Poland. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-05-15.

Sponsored by Institute of Psychiatry and Neurology, Warsaw · Not applicable, Interventional, and Prevention

How we know

The sponsor has not verified this record recently (last verified Apr 2012), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Ischemic Stroke with a site in Poland — 9 open to participants now, 11 under way, 2 of them phase 3. Ischemic Stroke · Poland.

Planned enrollment
14th of 26
240 · median 284
Started
2012
the only one that year
No phase
11 of 39
2 open now
Registered
7th of 39
by date
Lead sponsor
2 of 39
Institute of Psychiatry and Neurology, Warsaw

Among the 39 studies in Ischemic Stroke with a site in Poland, this one is the 14th largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2012, is one of 11 with no phase, and was the 7th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

9 of the 39 studies in Ischemic Stroke with a site in Poland are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Ischemic Stroke with a site in Poland, or all of them as a file.
02

Study summary

The primary objective of the present randomized controlled trial is to compare the effectiveness of three anti-smoking interventions of different intensities. It has been hypothesised that early follow-up visits facilitate post-stroke smoking cessation in patients hospitalized because of first-ever ischemic stroke.

Read the detailed description

BACKGROUND: It is well known, that continued smoking after stroke increases the risk of death and stroke recurrence within a few years after the first stroke. Searching for more efficient methods of antismoking interventions is therefore justified.

OBJECTIVES: The primary objective of the present study is to compare the effectiveness of three anti-smoking interventions of different intensities.

DESIGN: Randomized, controlled trial.

METHODS: Study participants will be recruited among patients of neurological clinics of Institute of Psychiatry and Neurology, hospitalized because of their first in a lifetime ischemic stroke. All stroke patients will be screened regarding their smoking status. The subjects will be patients smoking cigarettes immediately before their first-ever stroke, able to understand the research protocol procedures and able to cooperate during the investigation.

Antismoking interventions will be based on the "5A's" method. Study participants will be randomized to one of three interventions differing in follow-up intensity.

03

Conditions studied

  • Ischemic Stroke

Keywords

  • ischemic stroke
  • smoking cessation
  • antismoking interventions
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients smoking immediately prior to stroke
  • The first in the lifetime ischemic stroke
  • Ability to understand the research protocol procedures and cooperation during the investigation
  • Reported availability of and declaration to participate in follow-up
  • to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Severe stroke
  • Stroke onset more than 3 weeks before admission
  • History of previous stroke with clinical symptoms
  • Hemorrhagic stroke
  • Diagnosis of dementia or presence of other neurological disease (Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's chorea, a previous subarachnoid haemorrhage, meningitis, cerebral trauma in an interview)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Antismoking intervention with minimal early follow-up

    an intervention according to the "5A's" model with one follow-up visit within one week after discharge from the hospital; follow-up assessment will include two visits: 3 and 12 months after stroke

    Behavioral: Antismoking intervention with minimal early follow-up

  • Active comparator
    Antismoking intervention with no early follow-up

    an anti-smoking intervention in line with the "5A's" method without early follow-up; follow-up assessment will be limited to two visits: 3 and 12 months after stroke

    Behavioral: Antismoking intervention with no early follow-up

  • Experimental
    Antismoking intervention with intensive early follow-up

    an anti-smoking intervention in line with the "5A's" method will be given, including four follow-up visits within 6 weeks after discharge from the hospital (week 1, week 2, week 4, week 6 after stroke); follow-up assessment will include two visits: 3 and 12 months after stroke

    Behavioral: Antismoking intervention with intensive early follow-up

Interventions

  • BehavioralAntismoking intervention with no early follow-up

    an anti-smoking intervention in line with the "5A's" method without early follow-up; follow-up assessment will be limited to two visits: 3 and 12 months after stroke

  • BehavioralAntismoking intervention with minimal early follow-up

    Anti-smoking intervention in line with the "5A's" method (Ask, Advice, Assess, Assist, Arrange follow-up. The intervention will be carried out 5-7 days after stroke, before the planned discharge from the hospital. Seven days after discharge from a stroke unit a brief telephone/personal advice will be given aimed to motivate patients to quit smoking; follow-up assessment will include two visits: 3 and 12 months after stroke

  • BehavioralAntismoking intervention with intensive early follow-up

    an anti-smoking intervention in line with the "5A's" method will be given, including four follow-up visits within 6 weeks after discharge from the hospital (week 1, week 2, week 4, week 6 after stroke); follow-up assessment will include two visits: 3 and 12 months after stroke

06

What researchers measure

Primary outcomes

  1. Smoking cessation rate

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Institute of Psychiatry and Neurology
    Warsaw, 02-957, Poland
    Recruiting
    • Will · Contactneurol1@ipin.edu.pl · +48224582548
    • Halina Sienkiewicz-Jarosz, M.D., PhD · Principal investigator
    • Przemysław Bienkowski, M.D., Prof. · Sub investigator
    • Magdalena Restel, M.D. · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Dec 2013 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2012
First posted
Apr 10, 2012
Start
Apr 2012
Primary completionEst.
Dec 2013
CompletionEst.
Dec 2014
Last update
May 15, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01574001
Lead sponsor
Institute of Psychiatry and Neurology, Warsaw
Responsible party
Halina Sienkiewicz-Jarosz (Principal Investigator, Institute of Psychiatry and Neurology, Warsaw) — Principal investigator
First posted
Apr 10, 2012
Start date
Apr 2012
Primary completion
Dec 2013 (estimated)
Completion
Dec 2014 (estimated)
Last update
May 15, 2013

Study contacts

Halina Sienkiewicz-Jarosz, M.D., PhD
Contact
jarosz@ipin.edu.pl
+48224582548
Halina Sienkiewicz-Jarosz, M.D., PhD
principal investigator · 1st Department of Neurology, Institute of Psychiatry and Neurology, 9 Sobieskiego Str., 02-957 Warsaw, Poland

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion